Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Role of (myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice.

Bugyik E, Szabó V, Dezső K, Rókusz A, Szücs A, Nagy P, Tóvári J, László V, Döme B, Paku S.

Cancer Commun (Lond). 2018 Jul 5;38(1):46. doi: 10.1186/s40880-018-0316-x.

2.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
3.

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.

Clin Cancer Res. 2018 May 3. doi: 10.1158/1078-0432.CCR-17-1507. [Epub ahead of print]

PMID:
29724868
4.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
5.

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.

Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B.

Sci Rep. 2017 Nov 28;7(1):16456. doi: 10.1038/s41598-017-16551-7.

6.

BARD1 serum autoantibodies for the detection of lung cancer.

Pilyugin M, Descloux P, André PA, Laszlo V, Dome B, Hegedus B, Sardy S, Janes S, Bianco A, Laurent GJ, Irminger-Finger I.

PLoS One. 2017 Aug 7;12(8):e0182356. doi: 10.1371/journal.pone.0182356. eCollection 2017.

7.

Theoretical rationalization for reduced charge recombination in bulky carbazole-based sensitizers in solar cells.

Surakhot Y, Laszlo V, Chitpakdee C, Promarak V, Sudyoadsuk T, Kungwan N, Kowalczyk T, Irle S, Jungsuttiwong S.

J Comput Chem. 2017 May 5;38(12):901-909. doi: 10.1002/jcc.24751. Epub 2017 Feb 13.

PMID:
28192642
8.

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.

Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B.

Theranostics. 2017 Jan 1;7(2):400-412. doi: 10.7150/thno.16767. eCollection 2017.

9.

The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization.

Paku S, Laszlo V, Dezso K, Nagy P, Hoda MA, Klepetko W, Renyi-Vamos F, Timar J, Reynolds AR, Dome B.

J Pathol. 2017 Mar;241(4):441-447. doi: 10.1002/path.4855. Epub 2017 Jan 27.

PMID:
28026875
10.

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.

Mol Cancer Ther. 2016 Oct;15(10):2357-2369. Epub 2016 Aug 10.

11.

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B.

Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8.

PMID:
27288871
12.

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

Hoda MA, Rozsas A, Lang E, Klikovits T, Lohinai Z, Torok S, Berta J, Bendek M, Berger W, Hegedus B, Klepetko W, Renyi-Vamos F, Grusch M, Dome B, Laszlo V.

Oncotarget. 2016 Mar 22;7(12):13388-99. doi: 10.18632/oncotarget.7796.

13.

Gene-expression Profiling in Non-small Cell Lung Cancer with Invasion of Mediastinal Lymph Nodes for Prognosis Evaluation.

Grigoroiu M, Tagett R, Draghici S, Dima S, Nastase A, Florea R, Sorop A, Ilie V, Bacalbasa N, Tica V, Laszlo V, Mansuet-Lupo A, Damotte D, Klepetko W, Popescu I, Regnard JF.

Cancer Genomics Proteomics. 2015 Sep-Oct;12(5):231-42.

PMID:
26417026
14.

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G.

Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11.

15.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
16.

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Hegedűs B.

Pathol Oncol Res. 2015 Sep;21(4):957-68. doi: 10.1007/s12253-015-9916-9. Epub 2015 Mar 9.

PMID:
25749811
17.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, Cserepes M, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 May;10(5):738-46. doi: 10.1097/JTO.0000000000000492.

18.

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.

Garay T, Kenessey I, Molnár E, Juhász É, Réti A, László V, Rózsás A, Dobos J, Döme B, Berger W, Klepetko W, Tóvári J, Tímár J, Hegedűs B.

PLoS One. 2015 Feb 3;10(2):e0117021. doi: 10.1371/journal.pone.0117021. eCollection 2015.

19.

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.

20.

Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.

Torok S, Vegvari A, Rezeli M, Fehniger TE, Tovari J, Paku S, Laszlo V, Hegedus B, Rozsas A, Dome B, Marko-Varga G.

Br J Pharmacol. 2015 Feb;172(4):1148-63. doi: 10.1111/bph.12990. Epub 2015 Jan 12.

21.

Mechanism of tumour vascularization in experimental lung metastases.

Szabo V, Bugyik E, Dezso K, Ecker N, Nagy P, Timar J, Tovari J, Laszlo V, Bridgeman VL, Wan E, Frentzas S, Vermeulen PB, Reynolds AR, Dome B, Paku S.

J Pathol. 2015 Feb;235(3):384-96. doi: 10.1002/path.4464. Epub 2014 Dec 18.

PMID:
25319725
22.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
23.

[A professor of ophthalmology at the University of Harkov].

László VM.

Lege Artis Med. 2014 Mar;24(3):160. Hungarian. No abstract available.

PMID:
25137985
24.

Apelin promotes lymphangiogenesis and lymph node metastasis.

Berta J, Hoda MA, Laszlo V, Rozsas A, Garay T, Torok S, Grusch M, Berger W, Paku S, Renyi-Vamos F, Masri B, Tovari J, Groger M, Klepetko W, Hegedus B, Dome B.

Oncotarget. 2014 Jun 30;5(12):4426-37.

25.

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.

Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, Klikovits T, Hoda MA, Grusch M, Berger W, Klepetko W, Hegedus B, Dome B.

Eur J Cancer. 2014 Jul;50(10):1819-28. doi: 10.1016/j.ejca.2014.04.001. Epub 2014 Apr 22.

26.

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.

Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, Dome B, Arns M, Schenk P, Jakopovic M, Samarzija M, Brcic L, Filipits M, Laszlo V, Klepetko W, Berger W, Hegedus B.

Br J Cancer. 2014 Feb 18;110(4):984-90. doi: 10.1038/bjc.2013.815. Epub 2014 Jan 16.

27.

Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.

Rózsás A, Berta J, Rojkó L, Horváth LZ, Keszthelyi M, Kenessey I, László V, Berger W, Grusch M, Hoda MA, Török S, Klepetko W, Rényi-Vámos F, Hegedűs B, Döme B, Tóvári J.

PLoS One. 2013 Oct 14;8(10):e77459. doi: 10.1371/journal.pone.0077459. eCollection 2013.

28.

Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients.

Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, Hoda MA, Laszlo V, Ankersmit HJ, Harms L, Boyero S, de Felipe A, Saiz A, Dalmau J, Graus F.

Neurology. 2013 Oct 22;81(17):1500-6. doi: 10.1212/WNL.0b013e3182a9585f. Epub 2013 Sep 25. Review.

29.

Cell migration or cytokinesis and proliferation?--revisiting the "go or grow" hypothesis in cancer cells in vitro.

Garay T, Juhász É, Molnár E, Eisenbauer M, Czirók A, Dekan B, László V, Hoda MA, Döme B, Tímár J, Klepetko W, Berger W, Hegedűs B.

Exp Cell Res. 2013 Dec 10;319(20):3094-103. doi: 10.1016/j.yexcr.2013.08.018. Epub 2013 Aug 22.

PMID:
23973668
30.

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.

Hoda MA, Münzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, Sahin E, Bedeir A, Lackner A, Dome B, Setinek U, Filipits M, Eisenbauer M, Kenessey I, Török S, Garay T, Hegedus B, Catania A, Taghavi S, Klepetko W, Berger W, Grusch M.

Br J Cancer. 2012 Dec 4;107(12):1978-86. doi: 10.1038/bjc.2012.519. Epub 2012 Nov 20.

31.

Asthma endophenotypes and polymorphisms in the histamine receptor HRH4 gene.

Simon T, Semsei AF, Ungvári I, Hadadi E, Virág V, Nagy A, Vangor MS, László V, Szalai C, Falus A.

Int Arch Allergy Immunol. 2012;159(2):109-20. doi: 10.1159/000335919. Epub 2012 May 30.

PMID:
22653292
32.

Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.

Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H.

Urology. 2012 Sep;80(3):737.e13-8. doi: 10.1016/j.urology.2012.03.023. Epub 2012 May 17.

PMID:
22607948
33.

Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study.

Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, Rozsas A, Ostoros G, Laszlo V, Hofbauer H, Renyi-Vamos F, Klepetko W, Dome B, Ankersmit HJ.

Clin Chim Acta. 2012 Jul 11;413(13-14):1115-20. doi: 10.1016/j.cca.2012.03.008. Epub 2012 Mar 23.

34.

Histamine modulates multiple functional activities of monocyte-derived dendritic cell subsets via histamine receptor 2.

Simon T, Gogolák P, Kis-Tóth K, Jelinek I, László V, Rajnavölgyi E.

Int Immunol. 2012 Feb;24(2):107-16. doi: 10.1093/intimm/dxr107. Epub 2012 Jan 9.

PMID:
22232416
35.

Lack of angiogenesis in experimental brain metastases.

Bugyik E, Dezso K, Reiniger L, László V, Tóvári J, Tímár J, Nagy P, Klepetko W, Döme B, Paku S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):979-91. doi: 10.1097/NEN.0b013e318233afd7.

PMID:
22002424
36.

Lung cancer in never smokers.

Torok S, Hegedus B, Laszlo V, Hoda MA, Ghanim B, Berger W, Klepetko W, Dome B, Ostoros G.

Future Oncol. 2011 Oct;7(10):1195-211. doi: 10.2217/fon.11.100. Review.

PMID:
21992731
37.

Impact of histamine on dendritic cell functions.

Simon T, László V, Falus A.

Cell Biol Int. 2011 Oct;35(10):997-1000. doi: 10.1042/CBI20100844. Review.

PMID:
21933149
38.

A new mechanism for pillar formation during tumor-induced intussusceptive angiogenesis: inverse sprouting.

Paku S, Dezso K, Bugyik E, Tóvári J, Tímár J, Nagy P, Laszlo V, Klepetko W, Döme B.

Am J Pathol. 2011 Sep;179(3):1573-85. doi: 10.1016/j.ajpath.2011.05.033. Epub 2011 Aug 9.

39.

Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer.

Szarvas T, László V, Vom Dorp F, Reis H, Szendröi A, Romics I, Tilki D, Rübben H, Ergün S.

Int J Cancer. 2012 Jun 15;130(12):2922-9. doi: 10.1002/ijc.26343. Epub 2011 Sep 22.

40.

Histamine regulates relevant murine dendritic cell functions via H4 receptor.

Simon T, Laszlo V, Lang O, Buzas E, Falus A.

Front Biosci (Elite Ed). 2011 Jun 1;3:1414-24.

PMID:
21622146
41.

Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles.

György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, Kittel A, Nagy G, Falus A, Buzás EI.

Cell Mol Life Sci. 2011 Aug;68(16):2667-88. doi: 10.1007/s00018-011-0689-3. Epub 2011 May 11. Review.

42.

Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice.

Baghy K, Dezso K, László V, Fullár A, Péterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV, Kovalszky I.

Lab Invest. 2011 Mar;91(3):439-51. doi: 10.1038/labinvest.2010.172. Epub 2010 Oct 18.

43.

Expression and function of histamine H4 receptor in mouse splenic dendritic cells.

Simon T, Jelinek I, Apponyi G, László V, Rajnavölgyi E, Falus A.

Inflamm Res. 2010 Mar;59 Suppl 2:S201-3. doi: 10.1007/s00011-009-0130-7. No abstract available.

PMID:
19997860
44.

Multi-disciplinary characterisation of a sandstone surface crust.

Veerle C, Geert S, Matthieu B, Jan D, Björn de S, Tom S, Denis VL, Yoni de W, Marlina E, Laszlo V, Luc VH, Patric J.

Sci Total Environ. 2009 Oct 1;407(20):5417-27. doi: 10.1016/j.scitotenv.2009.06.040. Epub 2009 Jul 25.

PMID:
19632704
45.

Development of arterial blood supply in experimental liver metastases.

Dezso K, Bugyik E, Papp V, László V, Döme B, Tóvári J, Tímár J, Nagy P, Paku S.

Am J Pathol. 2009 Aug;175(2):835-43. doi: 10.2353/ajpath.2009.090095. Epub 2009 Jul 2.

46.

Architectural changes during regenerative and ontogenic liver growth in the rat.

Papp V, Dezsö K, László V, Nagy P, Paku S.

Liver Transpl. 2009 Feb;15(2):177-83. doi: 10.1002/lt.21665.

47.

Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes.

László V, Dezso K, Baghy K, Papp V, Kovalszky I, Sáfrány G, Thorgeirsson SS, Nagy P, Paku S.

Histochem Cell Biol. 2008 Nov;130(5):1005-14. doi: 10.1007/s00418-008-0482-z. Epub 2008 Jul 29.

PMID:
18663461
48.

Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.

Kiss R, Kiss B, Könczöl A, Szalai F, Jelinek I, László V, Noszál B, Falus A, Keseru GM.

J Med Chem. 2008 Jun 12;51(11):3145-53. doi: 10.1021/jm7014777. Epub 2008 May 7.

PMID:
18459760
49.

Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration.

Dezso K, Jelnes P, László V, Baghy K, Bödör C, Paku S, Tygstrup N, Bisgaard HC, Nagy P.

Am J Pathol. 2007 Nov;171(5):1529-37. Epub 2007 Sep 20.

50.

Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment.

Szarvas T, Kovalszky I, Bedi K, Szendroi A, Majoros A, Riesz P, Füle T, László V, Kiss A, Romics I.

Oncol Rep. 2007 Aug;18(2):405-9.

PMID:
17611663

Supplemental Content

Loading ...
Support Center